Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Seattle Genetics and Millennium: The Takeda Oncology Company have begun a Phase I clinical trial evaluating brentuximab vedotin (SGN-35) in combination with chemotherapy as a treatment for newly diagnosed systemic anaplastic large cell lymphoma (ALCL).
Subscribe to our email newsletter
The dose-escalation Phase I trial will evaluate the safety profile, pharmacokinetics and antitumour activity of brentuximab vedotin when administered sequentially or in combination with multi-agent front-line chemotherapy regimens.
The study is expected to enroll 60 patients across multiple centres in the US and Europe.
Brentuximab vedotin is an antibody-drug conjugate (ADC) directed to CD30, which is highly expressed in ALCL, and is being jointly developed by Seattle Genetics and Millennium.
Under the terms of collaboration agreement, Seattle Genetics will have rights to commercialise brentuximab vedotin in the US and Canada, while Millennium will have commercialisation rights in the rest of the world.